Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Soh Okano"'
Autor:
Makoto Kodama, Soh Okano, Shuko Nojri, Keiko Abe, Masayuki Fukata, Yoshihiro Nagase, Hiroko Kodama
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0300580 (2024)
Although a Western diet has been identified as a risk factor for Crohn's disease (CD), there is still controversy surrounding the specific foods that may contribute to the development of the disease. In this study, we examined the association between
Externí odkaz:
https://doaj.org/article/d6d2e9f4fb064363a698d00f65b9f9e7
Autor:
Minako Sako, Naoki Yoshimura, Akira Sonoda, Soh Okano, Miki Ueda, Maki Tezuka, Makiko Mine, Shingo Yamanishi, Koichi Hashimoto, Koichi Kobayashi, Masakazu Takazoe, Masayuki Fukata
Publikováno v:
Journal of the Anus, Rectum and Colon, Vol 5, Iss 4, Pp 426-432 (2021)
Objectives: Knowledge gaps exist in the use of biologics for pregnant patients with Crohn's disease (CD), especially the usage of ustekinumab (UST) and infliximab (IFX) infusion during the late gestation period. In this case series, we investigated p
Externí odkaz:
https://doaj.org/article/4f23d3bd862346dfb778df874437707d
Enterocolic Lymphocytic Phlebitis Treated Preoperatively with Biologics and Immunosuppressive Agents
Autor:
Soh Okano, Takashi Yao, Osamu Nomura, Akihito Nagahara, Toshiaki Hagiwara, Kiichi Sugimoto, Makoto Takahashi, Kazuhiro Sakamoto
Publikováno v:
Case Reports in Pathology, Vol 2022 (2022)
Enterocolic lymphocytic phlebitis is phlebitis of unknown etiology in which lymphocytes affect veins without arteries and shows evidence of systemic vasculitis in the intestinal wall and mesentery, mainly in the small intestine and colon. Although pa
Externí odkaz:
https://doaj.org/article/613df2323190401a8b17e1baf0123473
Autor:
Akira Sonoda, Naoki Yoshimura, Minako Sako, Soh Okano, Satoshi Saito, Masakazu Takazoe, Satomi Furukawa, Kinya Okamoto, Tetsuo Yamana, Hisateru Tachimori, Masayuki Fukata
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 10, p1337-1343, 7p
Autor:
Hisanori Utsunomiya, Yoichi Akazawa, Hiroya Ueyama, Tomoyo Iwano, Momoko Yamamoto, Ryota Uchida, Shotaro Oki, Nobuyuki Suzuki, Daiki Abe, Atsushi Ikeda, Tsutomu Takeda, Kumiko Ueda, Mariko Hojo, Yukinori Yube, Sanae Kaji, Soh Okano, Sho Tsuyama, Hidetaka Eguchi, Yasushi Okazaki, Masami Arai
Publikováno v:
Internal Medicine; 2023, Vol. 62 Issue 22, p3333-3339, 7p
Autor:
Masayuki Fukata, Akira Sonoda, Naoki Yoshimura, Minako Sako, Soh Okano, Satoshi Saito, Masakazu Takazoe, Satomi Furukawa, Kinya Okamoto, Tetsuo Yamana
BackgroundDiffuse mucosal inflammation in the duodenum that is distinct from peptic ulcer diseases has been repeatedly reported in patients with ulcerative colitis (UC). The pathogenesis of this complication remains uncertain, however, a colectomy fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8aac3b5065570edb3c019d03238b289
https://doi.org/10.21203/rs.3.rs-1511604/v1
https://doi.org/10.21203/rs.3.rs-1511604/v1
Autor:
Takashi Yao, Daisuke Kobayashi, Tomoki Tamura, Tetsuo Yamana, Keiko Abe, Makoto Kodama, Satomi Furukawa, Rikisaburo Sahara, Soh Okano
Publikováno v:
J Histochem Cytochem
Crohn’s disease (CD) is a gastrointestinal disorder of unknown etiology. CD-specific longitudinal ulcers show an association between disease pathogenesis and vasculature dysfunction. Granulomatous lymphangitis may also contribute to CD pathogenesis
Publikováno v:
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 117(2)
Dilatation of the colon in severe and fulminating ulcerative colitis is a sign of toxic megacolon and emergency surgery is usually the favored treatment option. Here we describe our experience with three cases of ulcerative colitis with megacolon in
Publikováno v:
Progress of Digestive Endoscopy. 94:49-51
Publikováno v:
Clinical journal of gastroenterology. 13(4)
We describe a case of refractory pouchitis successfully treated with tofacitinib. The patient was a 20-year-old woman diagnosed with ulcerative colitis at the age of 14 years. She underwent surgery at the age of 18 years for chronic active inflammati